MARKETS
Recent Investments
Carclo has made several investments that directly strengthen our Drug Delivery Device capability:
- Cleanroom expansions in both the US and Europe, supporting drug delivery components.
- New all-electric injection moulding machines providing the stability needed for tight-tolerance parts.
- Ongoing collaboration with major OEMs that drives continuous improvement in component performance and manufacturability.
- Enhanced materials and analytics capability
- LifeTech Solutions incubator providing a framework to channel future Drug Delivery innovation — our SYNCURA digital companion.
Why it matters
Drug delivery devices — pens, injectors, inhalers — are the critical interface between drug formulations and patients. Their design, reliability, usability and manufacturability directly impact therapy success, adherence, safety and scalability.
Carclo’s strength in this space matters because:
- We enable pharmaceutical companies to bring therapies to market with robust, high-quality delivery systems.
- Our history with inhalers and auto-injectors demonstrates proven capabilities.
- We support a range of parenteral delivery formats providing flexibility across therapy types.
- We create the bridge between legacy manufacturing and future-facing device innovation under LifeTech Solutions.
- Through initiatives like two-stage auto-injectors, re-usable/disposable pens, and eventually connected devices, we aim to deliver patient-centric, next-generation drug delivery solutions.